# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Hartaj Singh maintains Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Outperform.
Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, an...
Merck stock has gained 20% since Nov. 28; a technical signal suggests the rally isn't over. Keytruda approvals also drive o...
TD Cowen analyst Tara Bancroft downgrades Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Market Perform.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow ...
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Harpoon Therapeutics (NASDAQ:HARP) from Buy to Neutral and...
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24...